Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The proposed phase 1 clinical trial will investigate the safety and tolerability of
177Lu-CYT-500 in patients with metastatic prostate cancer and determine the optimal antibody
mass and dose of 177Lu to be used for further study.